<DOC>
	<DOC>NCT02806128</DOC>
	<brief_summary>Evaluate the effectiveness of the of kallikrein in the different drug frequency for acute anterior circulation cerebral infarction.</brief_summary>
	<brief_title>The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Kallikreins</mesh_term>
	<criteria>1. Age 18 to 80 years old; 2. First time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae (mRS = 02); 3. Acute anterior circulation cerebral infarction with large artery atherosclerotic etiology; 4. Ability to randomize within 48 h of time last known free of new ischemic symptoms. 5. National Institute of Health stroke scale(NIHSS) ranges from 7 to 22; 6. signed written informed consent. 1. Cerebral CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.; 2. Transient ischemic attack; 3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8; 4. Combined angiotensinconverting enzyme inhibitor(ACEI) less than 5 halftime (according to its instruction), or need to be treated with ACEI; 5. Past or present suffering from hemorrhagic tendency of the disease; 6. The investigator in consideration of the other condition that the patients doesn't fit to participate in this clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cerebral infarction</keyword>
	<keyword>kallikrein</keyword>
	<keyword>KLK</keyword>
</DOC>